|
|
Aptevo Therapeutics Inc
For the fiscal interval ending December 31 2022 company decreased a loss per share of $-0.84 per share compare to $-1.28 a year prior and EPS improved from $-1.50 per share from the preceding reporting period.
Revenues remained unscathed to $0.00 millions from $3.67 millions in the similar reporting period a year prior and sequentially from $0.00 millions.
Aptevo Therapeutics Inc Competitors, Market Share
Aptevo Therapeutics Inc Suppliers
|
![closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Candel Therapeutics Inc
Underlining the financial period ending December 31 2022 Candel Therapeutics Inc Deficit has expanded at $-0.15 per share, relative to the results of $1.54 per share a year prior reporting period, In the preceding reporting period the Biotechnology & Pharmaceuticals company realized $-0.30 per share.
Candel Therapeutics Inc Suppliers
Candel Therapeutics Inc Suppliers
|
|
Recently Reported Results |
|
Surrozen Inc
Surrozen Inc proclaimed $12.5 millions, in Revenue in the fourth quarter of 2022.
Surrozen Inc Competitors, Market Share
Surrozen Inc Suppliers
|
Ast Spacemobile Inc
Considering the October to December 31 2022 time-frame Ast Spacemobile Inc reached zero gain at $0.00 per share, relative to the recent numbers of $0.32 per share a year prior reporting period, In the prior reporting period the Communications Services company realized $-0.18 per share.
Ast Spacemobile Inc Competitors, Market Share
Ast Spacemobile Inc elevation Rates, Profitability, PE
|
|
Talaris Therapeutics Inc
As the earnings season of the October to December 31 2022 period resumes, many corporations have disclosed the earnings. In the thick of it, are various businesses in the Biotechnology & Pharmaceuticals industry. And today, Talaris Therapeutics Inc issued operating shortfall of $-19.825 millions, for the fiscal fourth quarter of 2022.
Talaris Therapeutics Inc Suppliers
Talaris Therapeutics Inc growth Rates, Profitability, PE
|
![Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons](../news/img/healthcare/Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons.jpg "Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons")
Inhibikase Therapeutics Inc
For the financial fourth quarter of 2022 Inhibikase Therapeutics Inc decreased a loss per share of $-0.17 per share compare to $-0.20 a year ago and EPS improved from $-0.18 per share from the preceding reporting period.
Revenues advanced sharply to $0.06 millions from $0.00 millions in the same reporting period a year ago and sequentially Revenue doubled by 771.842 % from $0.01 millions.
Inhibikase Therapeutics Inc Customers
Inhibikase Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement
|
|
Scynexis Inc
For the fourth quarter of 2022 earnings season SCYX decreased a loss per share of $-0.22 per share compare to $-1.08 a year ago and Income per Share improved from $-0.62 per share from the previous quarter.
Revenues increased sharply by 155.276 % to $1.52 millions from $0.60 millions in the same quarter a year ago and sequentially Revenue decreased by -2.119 % from $1.56 millions.
Scynexis Inc stock quotes, charts, profile
Scynexis Inc Suppliers
|
![pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "pills2_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
Disc Medicine Inc
The Major Pharmaceutical Preparations sector observers start to digest the fourth quarter of 2022 results. Today those observers observe operating loss of $-21.327 millions, from the Disc Medicine Inc , as it has not mentioned any revenue still, for the own October to December 31 2022 financial reporting period.
Disc Medicine Inc Competitors, Market Share
Disc Medicine Inc Revenue growth Rates
|
|
|
|
Recently Reported Results |
|
Better Therapeutics Inc
As the earnings season of the October to December 31 2022 season resumes, countless businesses have disclosed their earnings. In the thick of it, have been various constituents of the Medical Equipment & Supplies industry. As well as, today, BTTX disclosed operating deficit of $-8.322 millions, for the fourth quarter of 2022.
Better Therapeutics Inc stock quotes, charts, profile
Better Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement
|
![Bugatti_Veyron_By_Ritchyblack_Stefan_Krause_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common](../news/img/auto/Bugatti_Veyron_By_Ritchyblack_Stefan_Krause_(Own_work)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common.jpg "Bugatti_Veyron_By_Ritchyblack_Stefan_Krause_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common")
Auto Sales
Monthly, quarterly and annual vehicle sales
Vehicle production and Market share
|
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image8)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
Calithera Biosciences Inc
The investors did not anticipate any adjustments at the top-line during the the October to December 31 2022 reporting season at the CALA. But, they consider the company's operating loss which came in at $-7.346 millions, during the matching time.
Calithera Biosciences Inc Suppliers
Calithera Biosciences Inc Suppliers
|
![oil_Plataform_By_aherrero_(La_Gaviota_Uploaded_by_ecemaml)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/oil/oil_Plataform_By_aherrero_(La_Gaviota_Uploaded_by_ecemaml)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "oil_Plataform_By_aherrero_(La_Gaviota_Uploaded_by_ecemaml)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
Vantage Drilling International
An ordinary Revenue improvement in the October to December 31 2022, by 52.984 % to $76.19 millions helped to cut losses to $-1.33 per share, from $-1.79 in similar the financial reporting period a year ago.
Vantage Drilling International Customers
Vantage Drilling International Suppliers
|
![Drill_By_John_Campbell_[FAL],_via_Wikimedia_Commons](../news/img/oil/Drill_By_John_Campbell_[FAL],_via_Wikimedia_Commons.jpg "Drill_By_John_Campbell_[FAL],_via_Wikimedia_Commons")
Surrozen Inc
Surrozen Inc revealed $12.5 millions, in Revenue in the financial time-frame closing December 31 2022.
Surrozen Inc Suppliers
Surrozen Inc growth Rates, Profitability, PE
|
International Trade
The U.S. trade gap widened in December 2022, on the decline in exports and growth in imports.
|
Factory Orders
U.S. Factory orders grew again after dipping in the last month, but Shipments of durable goods fell by -0.73 % to $543 billions.
|
![Warehouse_By Cayco_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common](../news/img/warehouse/Warehouse_ByCayco___[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common.jpg "Warehouse_By Cayco_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common")
Retail Inventories
The retail inventories growth rate accelerated compare to the slow down in previous month, due to growing inventories at the car dealars.
|
![Sikh_wearing_turban_By_Photography_by_Harkanwal_Singh._(Harkanwal_Singh)__[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Common](../news/img/communication/Sikh_wearing_turban_By_Photography_by_Harkanwal_Singh._(Harkanwal_Singh)__[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Common.jpg "Sikh_wearing_turban_By_Photography_by_Harkanwal_Singh._(Harkanwal_Singh)__[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Common")
Ast Spacemobile Inc
Directing the thoughts to the fiscal interval closing Dec 31 2022 the Communications Services company reached balanced books at $0.00 per share, relative to the earnings of $0.32 per share a year ago reporting period, In the preceding reporting period the Ast Spacemobile Inc realized $-0.18 per share.
Ast Spacemobile Inc Suppliers
Ast Spacemobile Inc Revenue advance Rates
|
![Nokia_Lumia_900_By_Vernon_Chan__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Common](../news/img/communication/Nokia_Lumia_900_By_Vernon_Chan__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Common.jpg "Nokia_Lumia_900_By_Vernon_Chan__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Common")
Talaris Therapeutics Inc
The Biotechnology & Pharmaceuticals industry reporters start to scrutinize the fourth quarter of 2022 performance. Now they follow operating deficit of $-19.825 millions, from the TALS, which has not specified any revenue thus far, for the respective October to December 31 2022 reporting period.
Talaris Therapeutics Inc stock quotes, charts, profile
Talaris Therapeutics Inc Suppliers
|
|
Inhibikase Therapeutics Inc
For the financial period closing December 31 2022 IKT decreased a loss per share of $-0.17 per share compare to $-0.20 a year before and EPS improved from $-0.18 per share from the prior financial reporting period.
Revenues surged sharply to $0.06 millions from $0.00 millions in the similar financial reporting period a year before and sequentially Revenue doubled by 771.842 % from $0.01 millions.
Inhibikase Therapeutics Inc Competitors, Market Share
Inhibikase Therapeutics Inc growth Rates, Profitability, PE
|
|
Scynexis Inc
For the fourth quarter of 2022 Scynexis Inc decreased a loss per share of $-0.22 per share compare to $-1.08 a year before and EPS improved from $-0.62 per share from the preceding quarter.
Revenues surged sharply by 155.276 % to $1.52 millions from $0.60 millions in the same quarter a year before and sequentially Revenue decreased by -2.119 % from $1.56 millions.
Scynexis Inc Competitors, Market Share
Scynexis Inc Suppliers
|
Disc Medicine Inc
While the October to December 31 2022 reporting cycle continues, many companies have reported the numbers. Some of them, are various businesses in the Major Pharmaceutical Preparations industry. As well as, today, IRON reported operating shortfall of $-21.327 millions, for the fiscal fourth quarter of 2022.
Disc Medicine Inc Customers
Disc Medicine Inc Suppliers
|
![News_Ticker_By_bgilliard__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/stocks/News_Ticker_By_bgilliard__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "News_Ticker_By_bgilliard__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
Lm Funding America Inc
company announced very solid Revenue improvement of 692.169 % year on year to $1.12 millions in the October to December 31 2022 time-frame, but increased a loss per share at $-0.95.
Lm Funding America Inc stock quotes, charts, profile
Lm Funding America Inc Revenue improvement Rates
|
|
|
|
|
![workout_By_Nnu-12-22100541Tracy_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/interesting/workout_By_Nnu-12-22100541Tracy_(Own_work)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "workout_By_Nnu-12-22100541Tracy_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
_scan_pd.jpg "Tomography_(CAT)_scan_pd")